Journal
Microdosing GLP-1s: What the Evidence Actually Shows
No randomised trial has evaluated any dose below the studied range.
No randomised trial has evaluated any dose below the studied range. This piece sets out what is established on glp1 microdosing evidence, which record holds it, and what remains unverified — with the underlying figures published as tables and charts so the reasoning is checkable rather than asserted.
Key findings
- No randomised trial has evaluated any dose below the studied range.
- Every figure here is drawn from a dated capture or an FDA primary source.
- Regulatory framework and entity-specific claims are held to different evidence standards.
- Open fields render as explicit statuses, never as estimates.
- No provider pays for coverage or placement on this platform.
| Topic | glp1 microdosing evidence |
|---|---|
| Category | Evidence |
| Pricing captured | 2026-07-06 |
| Framework sources | FDA, verified 2026-07-23 |
| Provider relationship | No Public Evidence Found no financial relationship exists |
Below the studied range, nothing has been measured
SURMOUNT-1 studied 5, 10 and 15 mg. The 2.5 mg starting dose exists to build tolerance and was not a treatment arm. No randomised trial has evaluated any dose below the studied range for weight management.
Marketing for microdosing borrows efficacy figures from trials of substantially higher doses, which is the central problem with the claim rather than a footnote to it.
Where trial evidence stops transferring?
Evidence attaches to the studied product, in the studied population, at the studied dose, by the studied route. Each is a boundary, and compounded preparations frequently cross at least one.
A dose below the studied range crosses the dose boundary, where no effect has been measured at all. An altered dosage form crosses the route boundary, making bioavailability an open empirical question rather than an established one.
| # | Provider | Total / month | Format | Notes |
|---|---|---|---|---|
| 1 | NexLife | $110 | Injectable | Microdose, 12-month ($1,320). M2M $129. No membership, flat at every covered dose. Below every dose studied in |
| 2 | Oak Longevity | $133 | Injectable | Flat across doses, no subscription. Not available in California. |
| 3 | NexLife | $145 | Injectable | Standard injection, 12-month ($1,740). M2M $165. No membership, flat at every covered dose. |
| 4 | Shed | $149 | Injectable | Microdose programme. 2-month minimum. |
| 5 | NexLife | $165 | Oral / ODT | ODT, 12-month ($1,980). M2M $199. No trial has tested this dosage form. |
| 6 | Found | $169 | Injectable | 12-month prepaid. Medication included, flat across doses. |
| 7 | Shed | $175 | Injectable | 12-month prepaid. Increases at higher doses. |
| 8 | Mochi Health | $178 | Injectable | Membership required. Same price at all doses. |
| 9 | Henry Meds | $179 | Sublingual | Sublingual tablets or drops. |
| 10 | Eden | $198 | Injectable | Membership required for any medication. |
The test to apply to any claim
If a marketing claim cites a trial percentage, ask which of those four boundaries the product on offer crosses. In this market the answer is rarely none.
Every SURMOUNT figure describes the subcutaneous injection at labelled doses. Every STEP figure describes semaglutide 2.4 mg by injection. A sublingual preparation or a microdose tier quoting either number is quoting a different product.
| FDA-approved route | Total / month | Format | Notes |
|---|---|---|---|
| LillyDirect — Foundayo (orforglipron) | $149 | Oral / pill | 0.8 mg starter. Cheapest verified path to an FDA-approved oral GLP-1 for weight loss. Rises to $199/$299/$349 by dose. |
| NovoCare — Wegovy tablet | $149 | Oral / pill | 1.5 mg and 4 mg. Cheapest verified path to FDA-approved oral semaglutide. |
| LillyDirect — Zepbound vial | $299 | Injectable | 2.5 mg starter. 5 mg $399; 7.5–15 mg $449. 45-day refill rule. |
| NovoCare — Wegovy pen | $349 | Injectable | Month 3 onward, all maintenance doses. Cut from $499 in November 2025. |
What would settle it?
A pharmacokinetic study measuring bioavailability against the injectable reference, then dose equivalence, then content uniformity and stability in the specific dosage form.
None of that has been published for a compounded GLP-1 preparation. The honest statement is not 'less effective' and not 'similar' — it is unmeasured.
What would change this analysis?
Three things would. A final determination on the 503B bulks list proposal, which the closed docket now makes likely within months. A change in the approved-product pricing that has repriced the category — the $149 oral tier is recent and competitive pressure has been moving it. And any published pharmacokinetic work on compounded preparations, which would move several questions here from unmeasured to measured.
None of those is speculative. Each has a named decision-maker and, in two cases, a live process. This page carries its own date so the gap between what was checked and what is current stays visible.
How to check any of this yourself
Regulatory framework: FDA's compounding pages carry the statutory position and the declaratory orders that ended the shortage exception. Every framework claim on this platform links to one of them.
Facility status: FDA's registered outsourcing facility list is updated weekly and now publishes inspection dates, whether a Form 483 was issued, and the action status. State licensure sits with the relevant board of pharmacy — a different register, and the only one covering 503A pharmacies.
Pricing: every figure here is a dated capture against the provider's own published page, computed as a total. The full dataset is published as JSON and CSV so the arithmetic can be rerun.
Applying this to glp1 microdosing evidence
No randomised trial has evaluated any dose below the studied range.
Everything above is checkable against a named public record. Where this platform has not performed that check, the field renders as an explicit status rather than an inferred value — which tells you precisely what to go and confirm.
What this means
- Regulatory framework and dates are cited to FDA primary sources.
- Pricing figures are dated captures against provider pages, computed as totals.
- Every open field carries an explicit status rather than an estimate.
What this does not mean
- That any named entity is compliant, safe, or non-compliant.
- That a lower price indicates better evidence or quality.
- That this platform certifies or endorses any facility or preparation.
- Pricing captured 2026-07-06; confirm at checkout before relying on it.
- Regulatory positions change through rulemaking, guidance and enforcement action.
- Entity-specific licence and enforcement records are covered on the monitoring pages, not here.
- Nothing here is legal or medical advice.
Frequently asked questions
What is the short answer on glp1 microdosing evidence?
No randomised trial has evaluated any dose below the studied range.
Where do these figures come from?
Pricing from dated captures against provider pages (2026-07-06); regulatory facts from FDA primary sources.
Does any provider pay to appear here?
No. This platform has no affiliate, referral, sponsorship, or financial relationship with any provider.
How often is this updated?
When the underlying capture or regulatory position changes. Every page carries its own date.
Is this legal or medical advice?
No. It reports what named public records say on the dates they were checked. Clinical decisions belong with a prescriber and legal questions with a qualified adviser.
How can I check the figures myself?
The pricing dataset is published as JSON and CSV, the FDA register and inspection records are linked on every page that uses them, and each figure carries its capture date.
What if a record here is wrong?
Report it through the corrections process. Named entities can also respond through the right-to-respond route, and accepted corrections are logged with their date.
Sources
- GLP-1 pricing database
- FDA — Registered Outsourcing Facilities
- FDA — Information for Outsourcing Facilities
- FDA — Q&A: Outsourcing Facility Registration
Update history
| Date | Change |
|---|---|
| 2026-07-23 | Record published at current snapshot. |
Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.